Prognostic Value of Hypothalamic Copeptin in Acute Ischemic Stroke

Alemam, Aktham Ismail; Elwan, Mohamad Ezzat; Alahmar, Ibrahim Alsayed

doi:10.14740/jnr377w

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same finding was reported recently [15]. Lacunar infarction usually had a favorable outcome [3], and the larger the size of ischemic cerebral stroke, the more unfavorable outcome [14].…”

Section: Discussionsupporting

confidence: 86%

“…The CT brain was evaluated for the presence of any signs of early infarction [11], hyperdense middle cerebral artery (HMCA) sign [12], and estimating the size of infarction according to the rules [13]. The size was classified as small, medium, and large [14]. Magnetic resonance imaging (MRI) of the brain was done in suspected brain stem lesions, early ischemic stroke, and when follow-up CT brain is free.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Short-term outcome in ischemic stroke patients after thrombolytic therapy

Mohamed

Ghaffar

Gawad

et al. 2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Stroke represents the second leading cause of death in the world after myocardial infarction. Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (alteplase, rt-PA) is the only pharmacological therapy that was approved for treatment within 4.5 h of acute ischemic stroke (AIS) onset. We aimed to predict the 3-month outcome of AIS patients who received alteplase regarding mortality, spontaneous intra-cerebral hemorrhage (sICH), and functional outcome in comparison with non-thrombolyzed patients and to evaluate the predictors of the outcome after 3 months. Methods All the clinical, National Institute of Health Stroke Scale (NIHSS) scores, radiological, and laboratory data of 40 AIS patients and received rt-PA during the period from 2016 to 2018 were collected and analyzed retrospectively. For comparison, 40 patients, as a control group, were selected to match the alteplase group as regards the baseline data and received regular treatment, rather than rt-PA within the first 24 h, that were obtained. The outcome of the thrombolyzed patients after 3 months was evaluated in comparison with controls by using a modified ranking scale. Results After a 90-day follow-up period, the death rate was slightly higher among the rt-PA group (7.5%) in comparison with the control group (5%). sICH occurred in 7.5% of the patients in the alteplase group and in 5% of the non-thrombolyzed patients; however, this difference was not significant. More patients had a favorable outcome (mRS = 0–2) in the rt-PA group than in the control group (65% vs 60%, OR 1.38, 95% CI 0.50–3.6, P = 0.51). NIHSS score on admission, body mass index (BMI) (≥ 30), and previous transient ischemic attacks (TIA)/previous ischemic stroke were significant predictors of outcome after IV thrombolysis. Age, sex, hypertension (HTN), diabetes mellitus (DM), dyslipidemia, smoking, atrial fibrillation (AF), stroke subtype, size of infarction, and hyperdense middle cerebral artery had a non-significant effect. Conclusion After 3 months of follow-up, rt-PA had a non-significant more increase of favorable outcome with increased risk of sICH and death than controls. Baseline NIHSS, BMI, and history of TIA or previous ischemic stroke were significant predictors of outcome after thrombolysis.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Methodsmentioning

confidence: 99%

Short-term outcome in ischemic stroke patients after thrombolytic therapy

Mohamed

Ghaffar

Gawad

et al. 2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…Furthermore, copeptin levels predicted unfavorable functional prognosis and mortality in stroke patients. An improved prognosis accuracy was observed after adding copeptin measurements to the NIHSS or ABCD2 score, compared to using these scores alone [138,139].…”

Section: Copeptinmentioning

confidence: 98%

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Ion

Stafie

Mitu

et al. 2021

JCDD

View full text Add to dashboard Cite

Biomarkers are important diagnostic and prognostic tools as they provide results in a short time while still being an inexpensive, reproducible and accessible method. Their well-known benefits have placed them at the forefront of research in recent years, with new and innovative discoveries being implemented. Cardiovascular and neurological diseases often share common risk factors and pathological pathways which may play an important role in the use and interpretation of biomarkers’ values. Among the biomarkers used extensively in clinical practice in cardiology, hs-TroponinT, CK-MB and NTproBNP have been shown to be strongly influenced by multiple neurological conditions. Newer ones such as galectin-3, lysophosphatidylcholine, copeptin, sST2, S100B, myeloperoxidase and GDF-15 have been extensively studied in recent years as alternatives with an increased sensitivity for cardiovascular diseases, but also with significant results in the field of neurology. Thus, given their low specificity, the values interpretation must be correlated with the clinical judgment and other available investigations.

show abstract

Prognostic Value of Hypothalamic Copeptin in Acute Ischemic Stroke

Cited by 2 publications

References 23 publications

Short-term outcome in ischemic stroke patients after thrombolytic therapy

Short-term outcome in ischemic stroke patients after thrombolytic therapy

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Contact Info

Product

Resources

About